# 177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma

> **NCT04167618** · PHASE1,PHASE2 · TERMINATED · sponsor: **Y-mAbs Therapeutics** · enrollment: 2 (actual)

## Conditions studied

- Medulloblastoma, Childhood

## Interventions

- **DRUG:** 177Lu-DTPA-omburtamab

## Key facts

- **NCT ID:** NCT04167618
- **Lead sponsor:** Y-mAbs Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-09-30
- **Primary completion:** 2022-08-11
- **Final completion:** 2022-08-11
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Business priorities
- **Last updated:** 2023-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04167618

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04167618, "177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04167618. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*